IRhythm Technologies Inc. reported revenue of $192.9 million for the third quarter of 2025, representing a 30.7% increase compared to the third quarter of 2024. Gross margin for the period was 71.1%, an increase of 230 basis points year over year. As of September 30, 2025, the company had unrestricted cash, cash equivalents, and marketable securities totaling $565.2 million. Net loss for the third quarter of 2025 was $5.2 million, or a diluted loss of $0.16 per share, compared to a net loss of $46.2 million, or a diluted loss of $1.48 per share, for the same period in 2024. Adjusted net loss was $2.0 million, or a diluted loss of $0.06 per share, compared to an adjusted net loss of $39.2 million, or a diluted loss of $1.26 per share, in the prior year period. For the full year 2025, the company projects revenue between $735.0 million and $740.0 million, with an adjusted EBITDA margin expected to range from approximately 8.3% to 8.8% of revenues. Business developments in the period included continued momentum in the core long-term continuous monitoring business, sustained demand for Zio AT, progress within value-based care accounts, and contributions from international markets. The company reported the publication of real-world evidence and clinical trial data supporting the clinical value of its Zio long-term continuous monitoring service. iRhythm also advanced its innovation pipeline with the submission of its next-generation Zio MCT solution to the FDA and early work in sleep diagnostics.